Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$10.29 ▼ -0.36
(-3.38%)
MKT CAP: $647.0M • VOL: 1.03M
52W L $9 52W H $26
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$9
MEDIAN
$12
MEAN
$12
HIGH
$14
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE DBVT TAPE
DBVT // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $12.45 | $11.83 | 2025-02-14 | $9.36 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $12.97 | $12.14 | 2025-02-06 | $9.67 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $11.73 | $11.32 | 2025-01-29 | $9.88 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $10.50 | — | 2025-01-17 | $10.08 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $9.06 | $9.78 | 2025-01-09 | $9.16 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $12.25 | $10.70 | 2024-12-18 | $8.95 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $9.98 | $10.39 | 2024-12-04 | $9.57 | -4.3% | 48% | C |